期刊文献+

多囊卵巢综合征患者胰岛素抵抗和高胰岛素血症的诊治 被引量:45

Diagnosis and treatment of PCOS and insulin-resistance hyperinsulinemia
原文传递
导出
摘要 胰岛素抵抗(IR)是多囊卵巢综合征(PCOS)的重要病理生理改变。IR及高胰岛素血症是PCOS患者代谢异常的基本特征,也是PCOS患者内分泌代谢紊乱的主要特征之一。肥胖型PCOS患者高胰岛素血症发生率高达75%,非肥胖型PCOS患者约为30%。流行病学调查显示PCOS患者发生2型糖尿病、高血压、冠心病等疾病的风险明显增加,胰岛素抵抗可能在PCOS的发生中起着重要作用。生活方式改变和胰岛素增敏剂是治疗的有效方法。 Insulin resistance (IR) is the important physiopathologic change. IR and hyperinsulinemia are the basic characteristics of polycystic ovary syndrome (PCOS) , and they are also one of the main characteristics of PCOS patients with endocrine and metabolic disorders. The rate of hyperinsulinemia of the PCOS patients with obesity are about 75% , and 30% with none obesity patients. According to epidemiological investigation, the morbidity of non - insulin dependent diabetes mellitus(NIDDM) , hypertension and coronary heart disease increase in PCOS patients. IR may play an important role in pathogenesis of PCOS. Lifestyle modification and using insulin sensitizer are effective measures of PCOS with IR.
出处 《中国实用妇科与产科杂志》 CAS CSCD 北大核心 2013年第11期864-866,共3页 Chinese Journal of Practical Gynecology and Obstetrics
关键词 胰岛素抵抗 多囊卵巢综合征 高雄激素血症 胰岛素增敏剂 insulin resistance polycystic ovary syndrome hyperandrogenism insulin sensitizer
  • 引文网络
  • 相关文献

参考文献16

  • 1Li R, Zhang Q, Yang D, et al. Prevalence of polycystic ovary syndrome in women in China: a large community-based study [J]. Hum Repmd,2013 Jun 27. [Epub ahead of print]. 被引量:1
  • 2Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome role in an unselected population [J]. J Clin Endocrinol Metab,2004,89:2745-2749. 被引量:1
  • 3Fruzzetti F, Bersi C, Parrini D, et al. Effect of long-term naltrex- one treatment on endocrine, profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome [ J ]. Fertil Steri1,2002,77 ( 5 ) :936-944. 被引量:1
  • 4Romualdi D, Guido M, Calmpelli M, et al. Selective effects of pi- oglitazone on insulin and andlvgen abnormalities in normo and hyperinsulinaemic obese patients with polycystic ovary syndrome [ J ]. Hum Peprod ,2003,18 (6) : 1210-1218. 被引量:1
  • 5Baranowska B, Radzikowska M, Wasilewska DE, et al. Neuropep- tide Y, leptin, galanin and insulin in women with polycystic ovary syndrome [ J ]. Gynecol Endocrinol, 1999,13 ( 5 ) : 344-351. 被引量:1
  • 6La Marca A, Morgante G, Palumbo M, et al. Insulin-lowering treatment reduces aromatase activity in response to follicle-stimu- lating normone in women with polycystic ovary syndrome [ J ]. Fertil Steri1,2002,78 (6) : 1234-1239. c. 被引量:1
  • 7Chakraborty P, Goswami SK, Rajani S, et aL Recurrent preg- nancy loss in polycystic ovary syndrome: role of hyperhomocys- teinemia and insulin resistance [ J ]. PLoS One, 2013, 8 (5) : e64446, doi: 10. 1371. 被引量:1
  • 8Abbott DH, Bacha F. Ontogeny of polycystic ovary syndrome and insulin resistance in utero and early childhood[ J]. Fertil Steril, 2013,100( 1 ) :2-11. 被引量:1
  • 9Ciotta L, De Leo V, Farina M, et al. Endiocrine and metaboli effects of insulin sensitizers in the treatment of patients with poly- cystic ovary syndrome and hyperinsulinaemia[ J]. Gynecol Obstet Invest ,2001,51 ( 1 ) :44-50. 被引量:1
  • 10De Leo V, Musacchio MC, Morgante G, et al. Metformin treat- ment is effective in obese teenage girl with PCOS[ J]. Hum Re- prod ,2006,21 (9) :2252-2256. 被引量:1

同被引文献456

引证文献45

二级引证文献403

相关主题

;
使用帮助 返回顶部